{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-148865","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.058546+00:00","generated_at":"2026-05-15T06:48:43.163980+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Invivyd announces Phase 3 DECLARATION upsizing; new measles antibody VMS063","bullets":["DECLARATION Phase 3 COVID-19 prophylaxis study upsized by ~500 subjects; top-line results now expected in Q3 2026, shifted from mid-2026.","Pooled, blinded COVID-19 events at 1,500 subjects (Day 45) already support statistical power for high end of anticipated VYD2311 efficacy.","FDA alignment on initial Pediatric Study Plan for VYD2311 (DRUMMER study) for children aged 0-11 years, contingent on DECLARATION success.","New measles mAb candidate VMS063 targets F protein, shows potent in vitro neutralization (picogram/mL IC50s) across B3, D8, Edmonston lineages; IND-enablement started.","VMS063 is half-life extended, planned for treatment and prophylaxis in measles; U.S. measles incidence in 2026 on track to exceed 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-148865","json":"https://secwatch.observer/filing/0001193125-26-148865.json","markdown":"https://secwatch.observer/filing/0001193125-26-148865.md","text":"https://secwatch.observer/filing/0001193125-26-148865.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526148865/0001193125-26-148865-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312526148865/d147019d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:48:43.163980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}